CFD
Complement factor D
As of the edition of 20 October 2026, CFD (complement factor D, UniProt P00746) has 2 drugs tested at it and 2 companies on the list, 1 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P00746
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Secreted
- Solved structures
- 40
- Disease areas
- Blood and lymph; Eye; Pregnancy and women's health; Urinary and reproductive; Immune system; Infections; Lungs and airways
- Registered trials of its drugs
- 35
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Stopped | 1 |
| Total | 2 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Danicopan | Marketed | Phase 3 | Ends 2035 |
| Lampalizumab | Stopped | Phase 3 | none listed |
2 of 2 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 1 |
| Route B | 1 |
| Total on the list | 2 |
| Company | Route |
|---|---|
| AstraZeneca | Route B |
| Roche | Route A |
The other 0 companies at CFD
In the product2 companies in all; 0 are not named here, and no score is.
See the 2 companies at CFD, ranked, with the facts behind eachRequest access. Nothing is shown until you do.